The Bull Case For GlaxoSmithKline plc

Here’s why GlaxoSmithKline plc (LON: GSK) could be a top notch performer

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The pharmaceutical industry is a rather brutal place in which to exist. After all, it centres around spending a vast sum of money to eventually develop a drug, a period of patent protection where sales are high and profits are generous, before generic competition eats away at sales and turns a blockbuster drug into something of a ‘has-been’.

This cycle can be tough to cope with for many companies, with a number of major pharmaceutical stocks experiencing so-called patent cliffs, whereby their pipeline fails to keep up with the loss of patents and their sales fall significantly. And, while GlaxoSmithKline (LSE: GSK) has seen its sales come under pressure, it seems to have been able to better position itself to cope with such challenges than many of its sector peers.

Looking ahead, GlaxoSmithKline’s pipeline is hugely appealing, with a number of exciting new treatments being in late-stage trials. Notably, its ViiV Healthcare subsidiary has the potential to transform GlaxoSmithKline’s top and bottom lines, with its potential being so great that a spin-off was mooted earlier this year. And, with GlaxoSmithKline reducing its exposure to the consumer goods market via the sale of brands such as Lucozade and Ribena, it now has a greater focus on developing its pipeline and on allocating greater resources to research and development.

Alongside an excellent pipeline, GlaxoSmithKline is also seeking to make itself more efficient. For example, it is aiming to make £1bn in cost reductions in the coming years, with staff cuts apparently due to deliver a sizeable proportion of the planned savings. Furthermore, it has decided to keep dividends at their current level over the medium term which, while disappointing in the near-term for income-seekers, means that GlaxoSmithKline will be able to invest even more capital in its pipeline and in future growth opportunities. This should put it on a firmer footing for long term growth.

Of course, GlaxoSmithKline’s bottom line is forecast to rise by 12% next year. This could improve investor sentiment in the stock and, with it trading on a price to earnings (P/E) ratio of just 17.2, this equates to a very appealing price to earnings growth (PEG) ratio of 1.4. Furthermore, GlaxoSmithKline remains a top notch dividend play, with its yield of 6.1% being among the highest in the FTSE 100, thereby making the potential for impressive total returns relatively high.

Meanwhile, GlaxoSmithKline remains a very defensive stock. Certainly, by its very nature it will endure challenging periods when a loss of patents on blockbuster drugs is not neatly matched by the emergence of new, key treatments. However, its cycle is less closely aligned to that of the economic cycle than for most of its FTSE 100 peers, thereby making it a great investment to own during difficult periods for the wider market.

So, while its shares have disappointed in recent years, for example falling by 12% in the last ten years, it appears to be one of the most enticing long-term opportunities in the FTSE 100.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »